You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
|
|---|---|
| Published in |
Blood, April 2013
|
| DOI | 10.1182/blood-2012-11-464503 |
| Pubmed ID | |
| Authors |
Ulf-Henrik Mellqvist, Peter Gimsing, Oyvind Hjertner, Stig Lenhoff, Edward Laane, Kari Remes, Hlif Steingrimsdottir, Niels Abildgaard, Lucia Ahlberg, Cecilie Blimark, Inger Marie Dahl, Karin Forsberg, Tobias Gedde-Dahl, Henrik Gregersen, Astrid Gruber, Nina Guldbrandsen, Einar Haukås, Kristina Carlson, Ann Kristin Kvam, Hareth Nahi, Roald Lindås, Niels Frost Andersen, Ingemar Turesson, Anders Waage, Jan Westin, for the Nordic Myeloma Study Group |
| Abstract |
The Nordic Myeloma Study Group conducted an open randomized trial to compare bortezomib as consolidation therapy given after high-dose therapy and autologous stem cell transplantation (ASCT) with no consolidation in bortezomib-naive patients with newly diagnosed multiple myeloma. Overall, 370 patients were centrally randomly assigned 3 months after ASCT to receive 20 doses of bortezomib given during 21 weeks or no consolidation. The hypothesis was that consolidation therapy would prolong progression-free survival (PFS). The PFS after randomization was 27 months for the bortezomib group compared with 20 months for the control group (P = .05). Fifty-one of 90 patients in the treatment group compared with 32 of 90 controls improved their response after randomization (P = .007). No difference in overall survival was seen. Fatigue was reported more commonly by the bortezomib-treated patients in self-reported quality-of-life (QOL) questionnaires, whereas no other major differences in QOL were recorded between the groups. Consolidation therapy seemed to be beneficial for patients not achieving at least a very good partial response (VGPR) but not for patients in the ≥ VGPR category at randomization. Consolidation with bortezomib after ASCT in bortezomib-naive patients improves PFS without interfering with QOL. This trial was registered at www.clinicaltrials.gov as #NCT00417911. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 44% |
| Brazil | 1 | 11% |
| Canada | 1 | 11% |
| United Kingdom | 1 | 11% |
| France | 1 | 11% |
| Unknown | 1 | 11% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 4 | 44% |
| Members of the public | 3 | 33% |
| Practitioners (doctors, other healthcare professionals) | 2 | 22% |
Mendeley readers
The data shown below were compiled from readership statistics for 131 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Unknown | 130 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 26 | 20% |
| Other | 21 | 16% |
| Student > Master | 14 | 11% |
| Student > Ph. D. Student | 10 | 8% |
| Student > Bachelor | 9 | 7% |
| Other | 27 | 21% |
| Unknown | 24 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 76 | 58% |
| Biochemistry, Genetics and Molecular Biology | 5 | 4% |
| Nursing and Health Professions | 5 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
| Agricultural and Biological Sciences | 4 | 3% |
| Other | 9 | 7% |
| Unknown | 28 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 February 2022.
All research outputs
#3,600,935
of 25,373,627 outputs
Outputs from Blood
#4,626
of 33,239 outputs
Outputs of similar age
#29,703
of 205,940 outputs
Outputs of similar age from Blood
#51
of 258 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 33,239 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 205,940 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 258 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.